Novavax’s Updated COVID-19 Vaccine Now Authorized in Canada
GAITHERSBURG, Md., Dec. 5, 2023 /PRNewswire/ — Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that Health Canada has granted expanded authorization for Nuvaxovid™ XBB.1.5 Vaccine (Recombinant protein, Adjuvanted) (NVX-CoV2601) for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals aged 12 and older. The Public Health Agency of Canada’s National Advisory Committee on Immunization recommended XBB COVID-19 vaccines that target more recent, immune-evasive variants of the virus.1
Related news for (NVAX)
- Novavax’s Nuvaxovid™ 2025-2026 Formula COVID-19 Vaccine Approved in the U.S.
- Novavax Announces Convertible Debt Refinancing
- 24/7 Market News Snapshot 06 August, 2025 – Novavax Inc (NASDAQ:NVAX)
- Novavax Reports Second Quarter 2025 Financial Results and Operational Highlights
- Novavax’s H5N1 Vaccine Candidate Demonstrates Immunogenicity in Preclinical Study